Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL-1186 for acute postoperative orthopedic pain
CTR20261383Phase 3Active
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HL-1186 in acute postoperative pain (3 arms), sponsored by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. Primary endpoint: Sum of time-weighted pain intensity difference. Started Apr 2026; status: active.
02
Drugs
HL-1186
03
Conditions
acute postoperative pain
Beyond the preview
Go deeper on CTR20261383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261383.